X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5606) 5606
Publication (704) 704
Book Review (114) 114
Book Chapter (76) 76
Book / eBook (25) 25
Conference Proceeding (14) 14
Reference (4) 4
Dissertation (3) 3
Newsletter (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (3924) 3924
humans (2097) 2097
male (1873) 1873
index medicus (1670) 1670
rats (1571) 1571
cyclic amp - metabolism (1482) 1482
pharmacology & pharmacy (1244) 1244
phosphodiesterase inhibitors - pharmacology (1099) 1099
3',5'-cyclic-amp phosphodiesterases - antagonists & inhibitors (896) 896
mice (876) 876
female (800) 800
neurosciences (772) 772
biochemistry & molecular biology (760) 760
camp (733) 733
cyclic gmp - metabolism (700) 700
cells, cultured (698) 698
in vitro techniques (667) 667
dose-response relationship, drug (666) 666
cyclic amp (648) 648
cell biology (614) 614
phosphodiesterase (596) 596
signal transduction (582) 582
enzyme inhibitors - pharmacology (561) 561
cyclic nucleotide phosphodiesterases, type 4 (505) 505
cyclic-amp (502) 502
phosphorylation (498) 498
physiology (481) 481
rats, sprague-dawley (475) 475
nitric oxide (470) 470
activation (423) 423
3',5'-cyclic-amp phosphodiesterases - metabolism (414) 414
expression (413) 413
calcium - metabolism (399) 399
cyclic amp-dependent protein kinases - metabolism (392) 392
cgmp (386) 386
nitric-oxide (386) 386
signal transduction - drug effects (377) 377
colforsin - pharmacology (369) 369
kinetics (368) 368
proteins (350) 350
cyclic amp - physiology (346) 346
rats, wistar (346) 346
dependent protein-kinase (342) 342
adenylyl cyclases - metabolism (337) 337
rolipram (335) 335
calcium (332) 332
cells (322) 322
analysis (318) 318
phosphodiesterase inhibitors - therapeutic use (317) 317
3',5'-cyclic-gmp phosphodiesterases - antagonists & inhibitors (313) 313
cyclic gmp (305) 305
inhibition (305) 305
article (303) 303
1-methyl-3-isobutylxanthine - pharmacology (302) 302
signal transduction - physiology (302) 302
cell line (293) 293
cyclic nucleotide phosphodiesterases, type 5 (289) 289
physiological aspects (288) 288
cyclic adenylic acid (282) 282
time factors (281) 281
endocrinology & metabolism (270) 270
nitric oxide - metabolism (269) 269
kinases (266) 266
sildenafil citrate (266) 266
cyclic amp - pharmacology (264) 264
in-vitro (260) 260
research (260) 260
cyclic-nucleotide phosphodiesterases (259) 259
cyclic nucleotide phosphodiesterases, type 3 (247) 247
phosphoric diester hydrolases - metabolism (246) 246
receptors (245) 245
guinea pigs (239) 239
structure-activity relationship (239) 239
isoproterenol - pharmacology (238) 238
sildenafil (235) 235
chemistry, medicinal (233) 233
gene expression (222) 222
piperazines - pharmacology (222) 222
rodents (221) 221
cyclic gmp - pharmacology (219) 219
nitric-oxide synthase (216) 216
enzymes (214) 214
cyclic amp-dependent protein kinases - antagonists & inhibitors (213) 213
mice, inbred c57bl (213) 213
rolipram - pharmacology (213) 213
cyclic-nucleotide phosphodiesterase (212) 212
disease models, animal (212) 212
cyclic-gmp (211) 211
adenosine (208) 208
adult (208) 208
cardiac & cardiovascular systems (205) 205
protein kinases (205) 205
rat (202) 202
brain (200) 200
rabbits (198) 198
receptor (197) 197
inflammation (195) 195
protein kinase a (194) 194
protein-kinase (194) 194
adenylate-cyclase (193) 193
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (16) 16
UofT at Mississauga - Stacks (2) 2
Chemistry (A D Allen) - Stacks (1) 1
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Gerstein Science - Periodical Stacks (1) 1
Online Resources - Online (1) 1
UTL at Downsview - May be requested (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cellular Signalling, ISSN 0898-6568, 03/2016, Volume 28, Issue 3, pp. 204 - 213
Parathyroid hormone (PTH) is secreted from the parathyroid glands in response to low plasma calcium levels. Besides its classical actions on bone and kidney,... 
PDE | Adipocyte | cAMP | PTH | Lipolysis | PKA | CAMP | PRIMARY HYPERPARATHYROIDISM | ACTIVATION | PROTEIN-KINASE | GLUCOSE-INTOLERANCE | IDENTIFICATION | INSULIN SENSITIVITY | CELL BIOLOGY | HUMAN ADIPOSE-TISSUE | DISEASE | FAT | RESISTANCE | Lipolysis - drug effects | Receptor, Parathyroid Hormone, Type 1 - metabolism | Humans | Mitogen-Activated Protein Kinase 3 - antagonists & inhibitors | Sterol Esterase - metabolism | Adipocytes - cytology | Male | Parathyroid Hormone - pharmacology | Phosphoproteins - metabolism | Receptor, Parathyroid Hormone, Type 2 - metabolism | Cyclic AMP-Dependent Protein Kinases - antagonists & inhibitors | Phosphorylation - drug effects | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - chemistry | Cyclic AMP-Dependent Protein Kinases - metabolism | Adenylyl Cyclase Inhibitors - pharmacology | Mice, Inbred C57BL | Mitogen-Activated Protein Kinase 1 - antagonists & inhibitors | Cells, Cultured | Receptor, Parathyroid Hormone, Type 2 - genetics | Imines - pharmacology | Phosphodiesterase 4 Inhibitors - pharmacology | Animals | Carrier Proteins - metabolism | Mitogen-Activated Protein Kinase 3 - metabolism | Signal Transduction - drug effects | Adipocytes - metabolism | Receptor, Parathyroid Hormone, Type 1 - genetics | Mice | Protein Kinase Inhibitors - pharmacology | Mitogen-Activated Protein Kinase 1 - metabolism | Perilipin-1 | Vitamin D | Parathyroid hormone | Insulin resistance | Development and progression | Calcifediol | Alfacalcidol | Calcium-binding proteins | Lipase | Type 2 diabetes | Protein kinases | Proteins | Phosphorylation | Inhibitors | Pathways | Hormones | Kinases | Vitamins | Cell and Molecular Biology | Basic Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Cell- och molekylärbiologi | Medicinska och farmaceutiska grundvetenskaper
Journal Article
Chemical and Pharmaceutical Bulletin, ISSN 0009-2363, 2017, Volume 65, Issue 11, pp. 1058 - 1077
It has been hypothesized that selective inhibition of phosphodiesterase (PDE) 2A could potentially be a novel approach to treat cognitive impairment in... 
pyrazolo[1,5-a]pyrimidine | structure-based drug design | schizophrenia | phototoxicity | intramolecular hydrogen bond | phospodiesterase 2A | Phototoxicity | Pyrazolo[1,5-a]pyrimidine | Schizophrenia | Phospodiesterase 2A | Structure-based drug design | Intramolecular hydrogen bond | CHEMISTRY, MEDICINAL | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | NEGATIVE SYMPTOMS | PDE2A INHIBITORS | DIFFRACTION DATA | SYNAPTIC PLASTICITY | CHEMISTRY, MULTIDISCIPLINARY | ANTIPSYCHOTIC-DRUGS | ANIMAL-MODELS | CGMP | PHARMACOLOGY & PHARMACY | RAT-BRAIN | Cyclic Nucleotide Phosphodiesterases, Type 2 - antagonists & inhibitors | Pyridines - chemistry | Humans | Rats, Long-Evans | Cercopithecus aethiops | Cognition Disorders - metabolism | Male | Structure-Activity Relationship | Pyrimidines - chemistry | Dose-Response Relationship, Drug | Thermodynamics | Pyrazoles - chemistry | Molecular Structure | Phosphodiesterase Inhibitors - chemistry | Pyrazoles - pharmacology | Cell Survival - drug effects | Administration, Oral | Cyclic Nucleotide Phosphodiesterases, Type 2 - metabolism | Solubility | Phosphodiesterase Inhibitors - pharmacology | Rats | Pyrimidines - pharmacology | Cognition Disorders - drug therapy | Drug Discovery | Mice, Inbred ICR | Phosphodiesterase Inhibitors - administration & dosage | Pyrazines - chemistry | Animals | Mice | Mice, Inbred BALB C | Pyridines - pharmacology | Powder Diffraction | Pyrazines - pharmacology | COS Cells | 3T3 Cells
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 03/2017, Volume 23, Issue 5, pp. 1186 - 1192
Purpose: In this study, we aimed to validate our extensive preclinical data on phosphodiesterase 4 (PDE4) as actionable target in B-cell malignancies. Our... 
IN-VITRO | ONCOLOGY | ACUTE LYMPHOBLASTIC-LEUKEMIA | GENE-EXPRESSION | IBRUTINIB | CHRONIC LYMPHOCYTIC-LEUKEMIA | LYMPHOMA | RECEPTOR | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE | TARGETING BTK | T-CELLS | Humans | Middle Aged | Aminopyridines - adverse effects | Male | Cyclopropanes - adverse effects | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Drug-Related Side Effects and Adverse Reactions - pathology | Benzamides - administration & dosage | Cyclopropanes - administration & dosage | Neoplasms - genetics | Phosphodiesterase 4 Inhibitors - administration & dosage | Phosphodiesterase 4 Inhibitors - adverse effects | Aged, 80 and over | Adult | Cyclic Nucleotide Phosphodiesterases, Type 4 - drug effects | Female | B-Lymphocytes - pathology | Benzamides - adverse effects | Aminopyridines - administration & dosage | Cyclic Nucleotide Phosphodiesterases, Type 4 - genetics | Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | B-Lymphocytes - drug effects | Maximum Tolerated Dose | Aged | Neoplasms - pathology | Anorexia | Pharmacodynamics | Phosphodiesterase IV | Fatigue | AKT protein | Pharmacology | Prednisone | Kinases | Patients | 1-Phosphatidylinositol 3-kinase | Anticancer properties | Inhibitors | Lymphocytes B | Experimental design | Quality | Safety engineering | Biomarkers | Antitumor activity | Safety | Pharmacokinetics | Cancer | Neutropenia | Phosphodiesterase | clinical trial | cyclic-AMP | AKT | PI3K | phosphodiesterase 4 | Lymphoma
Journal Article
Circulation, ISSN 0009-7322, 04/2007, Volume 115, Issue 16, pp. 2159 - 2167
Background - Recent cell-based studies have found that cGMP synthesis and hydrolysis by phosphodiesterase ( PDE) appear compartmentalized, with nitric oxide... 
Phosphodiesterases, type 5 | Cyclic GMP | Contractility | Catecholamines | Nitric oxide synthase | Myocytes | Natriuretic peptides | catecholamines | CARDIAC & CARDIOVASCULAR SYSTEMS | STIMULATION | contractility | cyclic GMP | HEART-FAILURE | PROTEIN-KINASE-I | phosphodiesterases, type 5 | myocytes | NATRIURETIC-PEPTIDE | natriuretic peptides | INHIBITION | CYCLIC-GMP | NITRIC-OXIDE | INTRACELLULAR CGMP | PERIPHERAL VASCULAR DISEASE | nitric oxide synthase | GUANYLYL CYCLASE-A | Cyclic GMP - physiology | Cyclic Nucleotide Phosphodiesterases, Type 5 | Myocardial Contraction - physiology | Myocardial Contraction - drug effects | Male | Sulfones - pharmacology | Sildenafil Citrate | Cytosol - enzymology | Cyclic GMP-Dependent Protein Kinases - antagonists & inhibitors | Cyclic GMP-Dependent Protein Kinases - physiology | Atrial Natriuretic Factor - pharmacology | Receptors, Adrenergic, beta - drug effects | NG-Nitroarginine Methyl Ester - pharmacology | Cells, Cultured - drug effects | 3',5'-Cyclic-GMP Phosphodiesterases - physiology | Purines - pharmacology | Mice, Inbred C57BL | Cells, Cultured - physiology | Phosphodiesterase Inhibitors - pharmacology | Guanylate Cyclase - metabolism | Nitric Oxide - physiology | Receptors, Adrenergic, beta - physiology | Enzyme Activation - drug effects | Piperazines - pharmacology | Cell Compartmentation - physiology | Cell Membrane - enzymology | Animals | Myocytes, Cardiac - drug effects | Myocytes, Cardiac - physiology | 3',5'-Cyclic-GMP Phosphodiesterases - antagonists & inhibitors | Isoproterenol - pharmacology | Second Messenger Systems - physiology | Mice | Protein Kinase Inhibitors - pharmacology
Journal Article
Cell, ISSN 0092-8674, 2005, Volume 123, Issue 1, pp. 25 - 35
Phosphodiesterases (PDEs) regulate the local concentration of 3′,5′ cyclic adenosine monophosphate (cAMP) within cells. cAMP activates the cAMP-dependent... 
PROTEIN-KINASE-A | CYCLIC-AMP | CAMP-SPECIFIC PHOSPHODIESTERASE | SUDDEN-DEATH | PHOSPHORYLATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | CARDIAC MYOCYTES | VENTRICULAR MYOCYTES | RELEASE | FAILING HEARTS | CA2+ LEAK | CELL BIOLOGY | Phosphorylation | Arrhythmias, Cardiac - chemically induced | Cyclic Nucleotide Phosphodiesterases, Type 4 | Heart Failure - enzymology | Cyclic Nucleotide Phosphodiesterases, Type 3 | Ryanodine Receptor Calcium Release Channel - metabolism | Myocytes, Cardiac - enzymology | 3',5'-Cyclic-AMP Phosphodiesterases - deficiency | Arrhythmias, Cardiac - genetics | Disease Models, Animal | Cyclic AMP-Dependent Protein Kinases - metabolism | Enzyme Inhibitors - adverse effects | 3',5'-Cyclic-AMP Phosphodiesterases - metabolism | Heart Failure - genetics | Mice, Transgenic | 3',5'-Cyclic-AMP Phosphodiesterases - genetics | Mice, Knockout | Myocardium - enzymology | Animals | 3',5'-Cyclic-AMP Phosphodiesterases - antagonists & inhibitors | Muscle Contraction - physiology | Arrhythmias, Cardiac - enzymology | Mice | Heart Failure - chemically induced | Macromolecular Substances - metabolism | Heart failure | Cyclic adenylic acid | Research | Arrhythmia | Phosphodiesterases | Risk factors | Medical colleges | Medical societies | Cardiac patients | Esterases | Adenylic acid | Protein kinases | Heart attack
Journal Article
Journal Article
Nature, ISSN 0028-0836, 2015, Volume 519, Issue 7544, pp. 472 - 476
Journal Article
Cell Reports, ISSN 2211-1247, 03/2016, Volume 14, Issue 11, pp. 2599 - 2610
Journal Article
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 2004, Volume 14, Issue 18, pp. 4607 - 4613
Journal Article
Journal Article
Journal Article
Psychopharmacology, ISSN 0033-3158, 6/2018, Volume 235, Issue 6, pp. 1793 - 1805